Liraglutide, a long-acting GLP-1 mimetic, and its metabolite attenuate inflammation after intracerebral hemorrhage

Journal of Cerebral Blood Flow and Metabolism

Volumn 32, Issue 12, 2012, Pages 2201-2210

  Hou, Jack ^a,b,c   Manaenko, Anatol ^a   Hakon, Jakob ^c   Hansen Schwartz, Jacob ^c   Tang, Jiping ^a   Zhang, John H ^a,b  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

^c International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

Author keywords

GLP 1(9 36)a; glucagon like peptide 1; inflammation; intracerebral hemorrhage; neuroprotection

Indexed keywords

CYCLIC AMP; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 (9-36)A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIRAGLUTIDE; PROTEIN KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN INJURY; CONTROLLED STUDY; MALE; MOUSE; NERVOUS SYSTEM INFLAMMATION; NEUROLOGIC DISEASE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BIOMIMETIC MATERIALS; BRAIN EDEMA; CEREBRAL HEMORRHAGE; DIPEPTIDYL PEPTIDASE 4; GLUCAGON-LIKE PEPTIDE 1; INFLAMMATION; MALE; MICE; NEUROPROTECTIVE AGENTS; PHOSPHORYLATION;

EID: 84870609729     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2012.133     Document Type: Article

References (41)

1. Morgenstern LB, Hemphill JC, Anderson C, Becker K, Broderick JP, Connolly ES et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals form the American Heart Association/ American Stroke Association. Stroke 2010; 41: 276-309.
2. Aronowski J, Zhao X. Molecular pathophysiology of cerebral hemorrhage: secondary brain injury. Stroke 2011; 42: 1781-1786.
3. Wang J, Doré S. Inflammation after intracerebral hemorrhage. J Cereb Blood Flow Metab 2007; 27: 894-908.
4. Larsen PJ, Holst JJ. Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter. Regul Pept 2005; 128: 97-107.
5. Anagnostis P, Athyros VG, Adamidou F, Panagiotou A, Kita M, Karagiannis A et al. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes Metab 2011; 13: 302-312.
6. Irwin DM. Molecular evolution of proglucagon. Regul Pept 2001; 98: 1-12.
7. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995; 80: 952-957.
8. Rolin B, Deacon CF, Carr RD, Ahre'n B. The major glucagon-like peptide-1 metabolite, GLP-1-(9-36)-amide, does not affect glucose or insulin levels in mice. Eur J Pharmacol 2004; 494: 283-288.
9. Dozier KC, Cureton EL, Kwan RO, Curran B, Sadjadi J, Victorino GP. Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation. Peptides 2009; 30: 1735-1741.
10. Arakawa M, Mita T, Azuma K, Ebato C, Goto H. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010; 59: 1030-1037.
11. Hattori Y, Jojima T, Tomizawa A, Satoh H, Hattori S, Kasai K et al. A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Diabetologia 2010; 53: 2256-2263.
12. Kodera R, Shikata K, Kataoka HU, Takatsuka T, Miyamoto S, Sasaki M et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its antiinflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 2011; 54: 965-978.
13. Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci USA 1992; 89: 8641-8645.
14. Iwai T, Ito S, Tanimitsu K, Udagawa S, Oka J. Glucagon-like peptide-1 inhibits LPSinduced IL-1beta production in cultured rat astrocytes. Neurosci Res 2006; 55: 352-360.
15. Teramoto S, Miyamoto N, Yatomi K, Oishi H, Arai H, Hattori N et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia. J Cereb Blood Flow Metab 2011; 31: 1696-1705.
16. Kolligs F, Fehmann HC, Go ke R, Go ke B. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes 1995; 44: 16-19.
17. Ramamurthy S, Ronnett GV. Developing a head for energy sensing: AMP-activated protein kinase as a multifunctional metabolic sensor in the brain. J Physiol 2006; 574: 85-93.
18. Ma Q, Huang B, Khatibi N, Rolland II W, Suzuki H, Zhang JH et al. PDGFR-a inhibition preserves blood-brain barrier after intracerebral hemorrhage. Ann Neurol 2011; 70: 920-931.
19. Kim KR, Rhee SD, Kim HY, Jung WH, Yang SD, Kim SS et al. KR-62436, 6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino} nicotinonitrile, is a novel dipeptidyl peptidase-IV (DPP-IV) inhibitor with anti-hyperglycemic activity. Eur J Pharmacol 2005; 518: 63-70.
20. Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009; 58: 975-983.
21. Knudsen LB, Nielsen PF, Huusfeldt PO, Johansen NL, Madsen K, Pedersen FZ et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000; 43: 1664-1669.
22. Schirra J, Sturm K, Leicht P, Arnold R, Go? ke B, Katschinski M. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. J Clin Invest 1998; 101: 1421-1430.
23. Manaenko A, Lekic T, Sozen T, Tsuchiyama R, Zhang JH, Tang J. Effect of gap junction inhibition on intracerebral hemorrhage-induced brain injury in mice. Neurol Res 2009; 31: 173-178.
24. Perry T, Greig NH. The glucagon-like peptides: a double-edged therapeutic sword? Trends Pharmacol Sci 2003; 24: 377-383.
25. Feigin VL, Lawes CM, Bennett DA, Anderson CS. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol 2003; 2: 43-53.
26. Xue M, Del Bigio MR. Intracortical hemorrhage injury in rats: relationship between blood fractions and brain cell death. Stroke 2000; 31: 1721-1727.
27. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989; 320: 325-376.
28. Stern M, Savill J, Haslett C. Human monocyte-derived macrophage phagocytosis of senescent eosinophils undergoing apoptosis. Mediation by alpha v beta 3/ CD36/thrombospondin recognition mechanism and lack of phlogistic response. Am J Pathol 1996; 149: 911-921.
29. Knudsen LB. Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes. J Med Chem 2004; 47: 4128-4134.
30. Kimura K, Iguchi Y, Inoue T, Shibazaki K, Matsumoto N, Kobayashi K et al. Hyperglycemia independently increases the risk of early death in acute spontaneous intracerebral hemorrhage. J Neurol Sci 2007; 255: 90-94.
31. Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002; 87: 1239-1246.
32. Takei K, Tokuyama K, Kato M, Morikawa A. Role of cyclic adenosine monophosphate in reducing superoxide anion generation in guinea pig alveolar macrophages. Pharmacology 1998; 57: 1-7.
33. Stevens CF. CREB and memory consolidation. Neuron 1994; 13: 769-770.
34. Kitagawa K. CREB and cAMP response element-mediated gene expression in the ischemic brain. FEBS J 2007; 274: 3210-3217.
35. Hickenbottom SL, Grotta JC, Strong R, Denner LA, Aronowski J. Nuclear factorkappaB and cell death after experimental intracerebral hemorrhage in rats. Stroke 1999; 30: 2472-2477.
36. Zhao X, Zhang Y, Strong R, Zhang J, Grotta JC, Aronowski J. Distinct patterns of intracerebral hemorrhage-induced alterations in NF-kappaB subunit, iNOS, and COX-2 expression. J Neurochem 2007; 101: 652-663.
37. Pala L, Pezzatini A, Dicembrini I, Ciani S, Gelmini S, Vannelli BG et al. Different modulation of dipeptidyl peptidase-4 activity between microvascular and macrovascular human endothelial cells. Acta Diabetol 2010 [e-pub ahead of print].
38. Gong C, Hoff JT, Keep RF. Acute inflammatory reaction following experimental intracerebral hemorrhage in rat. Brain 2000; 871: 57-65.
39. Osuka K, Watanabe Y, Usuda N, Atsuzawa K, Yoshida J, Takayasu M. Modification of endothelial nitric oxide synthase through AMPK after experimental subarachnoid hemorrhage. J Neurotrauma 2009; 26: 1157-1165.
40. Malm-Erjefa?lt M, Bjørnsdottir I, Vanggaard J, Helleberg H, Larsen U, Oosterhuls B et al. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos 2010; 38: 1944-1953.
41. Simonsen L, Holst JJ, Deacon CF. Exendin-4 but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs. Diabetologia 2006; 49: 706-712.